EE04223B1 - Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid - Google Patents

Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid

Info

Publication number: EE04223B1
Authority: EE; Estonia
Prior art keywords: interferon; liquid; amino acids; liquid formulation; formulation containing
Prior art date: 1996-12-24

Application number

EEP199900313A

Other languages

English (en)

Other versions

EE9900313A (et

Inventor

D. Dibiasi Mary

Staples Mark

Chung Wen-Li

Scharin Eric

Original Assignee

Biogen, Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-24

Filing date

1997-12-23

Publication date

2004-02-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21875893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04223(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-12-23 Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated

2000-04-17 Publication of EE9900313A publication Critical patent/EE9900313A/et

2004-02-16 Publication of EE04223B1 publication Critical patent/EE04223B1/et

Links

102000014150 Interferons Human genes 0.000 title abstract 4
108010050904 Interferons Proteins 0.000 title abstract 4
229940079322 interferon Drugs 0.000 title abstract 4
150000001413 amino acids Chemical class 0.000 title abstract 3
239000012669 liquid formulation Substances 0.000 title 1
239000007788 liquid Substances 0.000 abstract 6
239000000203 mixture Substances 0.000 abstract 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
102000003996 Interferon-beta Human genes 0.000 abstract 2
108090000467 Interferon-beta Proteins 0.000 abstract 2
229960001388 interferon-beta Drugs 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
230000002378 acidificating effect Effects 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000463 material Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000001179 sorption measurement Methods 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Immunology (AREA)
Virology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Zoology (AREA)
Hospice & Palliative Care (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
AIDS & HIV (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EEP199900313A 1996-12-24 1997-12-23 Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid EE04223B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3435396P	1996-12-24	1996-12-24
PCT/US1997/023817 WO1998028007A1 (en)	1996-12-24	1997-12-23	Stable liquid interferon formulations

Publications (2)

Publication Number	Publication Date
EE9900313A EE9900313A (et)	2000-04-17
EE04223B1 true EE04223B1 (et)	2004-02-16

Family

ID=21875893

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EEP200300127A EE04266B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon
EEP199900313A EE04223B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon, mis sisaldab aminohappeid

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EEP200300127A EE04266B1 (et)	1996-12-24	1997-12-23	Interferooni stabiilne vedelkompositsioon

Country Status (27)

Country	Link
EP (1)	EP0948358B2 (et)
JP (5)	JP4878664B2 (et)
KR (2)	KR101042660B1 (et)
CN (2)	CN1222315C (et)
AT (1)	ATE270899T1 (et)
AU (1)	AU738362B2 (et)
BG (2)	BG65418B1 (et)
BR (1)	BR9714434A (et)
CA (1)	CA2275890C (et)
CZ (1)	CZ300636B6 (et)
DE (1)	DE69729880T3 (et)
DK (1)	DK0948358T4 (et)
EA (1)	EA002754B1 (et)
EE (2)	EE04266B1 (et)
ES (1)	ES2224290T5 (et)
HU (1)	HU224222B1 (et)
IL (1)	IL130524A (et)
IS (1)	IS2070B (et)
MX (1)	MX337876B (et)
NO (1)	NO327844B1 (et)
NZ (2)	NZ336548A (et)
PL (1)	PL193447B1 (et)
PT (1)	PT948358E (et)
SI (1)	SI0948358T2 (et)
SK (1)	SK284989B6 (et)
TR (1)	TR199901968T2 (et)
WO (1)	WO1998028007A1 (et)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030190307A1 (en)	1996-12-24	2003-10-09	Biogen, Inc.	Stable liquid interferon formulations
SI0948358T2 (sl) *	1996-12-24	2012-03-30	Biogen Idec Inc	Stabilne tekoče formulacije interferona
DK1017413T4 (da) *	1997-09-23	2008-03-25	Rentschler Biotech Gmbh	Flydende formulering af interferon-beta
ATE359809T1 (de) *	1999-05-31	2007-05-15	Mitsubishi Chem Corp	Gefriergetrocknete hgf-präparationen
US6887462B2 (en)	2001-04-09	2005-05-03	Chiron Corporation	HSA-free formulations of interferon-beta
UY27373A1 (es) *	2001-07-09	2003-02-28	Schering Ag	Formulaciones de interferón beta-humano
RU2357751C2 (ru)	2001-12-21	2009-06-10	Ново Нордиск Хелт Кэр Аг	Жидкая композиция полипептидов фактора vii
WO2003061687A1 (fr) *	2002-01-18	2003-07-31	Asahi Kasei Pharma Corporation	Preparation a concentration elevee de thrombomoduline soluble
BRPI0311959B8 (pt)	2002-06-21	2021-05-25	Novo Nordisk Healthcare Ag	composição, métodos para preparar um polipeptídeo estável do fator vii, e para tratar uma síndrome responsiva do fator vii, e, uso do polipeptídeo do fator vii
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7897734B2 (en)	2003-03-26	2011-03-01	Novo Nordisk Healthcare Ag	Method for the production of proteins
TWI272948B (en)	2003-05-01	2007-02-11	Ares Trading Sa	HSA-free stabilized interferon liquid formulations
AR044302A1 (es) *	2003-05-13	2005-09-07	Ares Trading Sa	Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
RU2364609C2 (ru)	2003-05-23	2009-08-20	Ново Нордиск Хелт Кэр Аг	Стабилизация белка в растворе
CN1318087C (zh) *	2003-06-06	2007-05-30	北京三诺佳邑生物技术有限责任公司	去白蛋白神经生长因子制剂
AU2004264282B2 (en)	2003-08-14	2010-10-14	Novo Nordisk Health Care Ag	Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
BRPI0416042A (pt) *	2003-11-13	2007-01-02	Alza Corp	composição e aparelho para suprimento transdérmico
EP1532983A1 (en) *	2003-11-18	2005-05-25	ZLB Bioplasma AG	Immunoglobulin preparations having increased stability
KR20150138427A (ko)	2003-12-19	2015-12-09	노보 노르디스크 헬스 케어 악티엔게젤샤프트	인자 ｖｉｉ 폴리펩티드의 안정화된 조성물
MXPA06014079A (es) *	2004-06-01	2007-02-15	Ares Trading Sa	Metodo para estabilizar proteinas.
KR101149454B1 (ko) *	2004-08-24	2012-05-25	간가와 겐지	생리활성 펩티드의 액상 제제
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
ES2318575T3 (es) *	2004-11-10	2009-05-01	Novartis Vaccines And Diagnostics, Inc.	Interferon beta desamidado.
CN107028760B (zh) *	2005-01-12	2019-11-01	比奥根Ma公司	运输干扰素-β的方法
US20060188555A1 (en) *	2005-01-21	2006-08-24	Micheal Cormier	Therapeutic peptide formulations with improved stability
ATE501248T1 (de)	2005-07-02	2011-03-15	Arecor Ltd	Stabile wässrige systeme mit proteinen
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
JP5812318B2 (ja) *	2007-12-04	2015-11-11	レメディーファーマシューティカルズ，インコーポレイテッド	凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
BRPI0821029A2 (pt)	2007-12-20	2015-06-16	Merck Serono Sa	Fomulações de peg-interferon-beta
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
WO2009133408A2 (en)	2008-05-01	2009-11-05	Arecor Limited	Protein formulation
EP2328607A1 (en)	2008-07-16	2011-06-08	Arecor Limited	Stable formulation of a therapeutic protein
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
DE102008051574A1 (de)	2008-10-14	2010-04-15	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Verfahren zur Herstellung von Interferon-beta und deren Varianten
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
DE102009032179A1 (de)	2009-07-07	2011-01-13	Biogenerix Ag	Verfahren zur Reinigung von Interferon beta
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
JP6078344B2 (ja)	2010-02-04	2017-02-08	ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト	免疫グロブリン製剤
EP2361636A1 (en)	2010-02-26	2011-08-31	CSL Behring AG	Immunoglobulin preparation and storage system for an immunoglobulin preparation
DE102010011430A1 (de) *	2010-03-15	2011-09-15	Kurt Koch	Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN103260616B (zh) *	2010-12-09	2015-09-09	丸石制药株式会社	对乙酰氨基酚的稳定化剂
WO2012125809A1 (en)	2011-03-15	2012-09-20	Biogen Idec Inc.	Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP2838571A4 (en) *	2012-04-19	2016-02-10	Bard Inc C R	INFUSATE WITH INCREASED PH STABILITY IN ETHYLENE OXIDE STERILIZATION
EP3685839A1 (en)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin for use in the treatment of albuminuria and kidney related diseases
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ITMI20120913A1 (it)	2012-05-28	2013-11-29	Nicoletta Maxia	Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
CN103143000B (zh) *	2013-03-07	2014-11-05	安徽安科生物工程（集团）股份有限公司	一种重组人干扰素α2b制剂
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
JP2014208669A (ja) *	2014-06-17	2014-11-06	株式会社スリー・ディー・マトリックス	タンパク質の凝集抑制剤
HUE052280T2 (hu)	2014-12-03	2021-04-28	Csl Behring Ag	Immunoglobulinokat tartalmazó megnövelt stabilitású gyógyszerészeti termék
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
KR101943160B1 (ko) *	2016-10-06	2019-01-30	에이비온 주식회사	인터페론 베타 변이체의 안정화 제제
AU2018321335B2 (en)	2017-08-22	2025-08-14	Biogen Ma Inc.	Pharmaceutical compositions containing anti-beta amyloid antibodies
KR102731889B1 (ko) *	2019-07-18	2024-11-19	에이비온 주식회사	2당화된 인터페론-베타 단백질의 정제 방법
CN110714051B (zh) *	2019-11-20	2023-04-07	迈克生物股份有限公司	蛋白c活性测定试剂盒
CA3177028A1 (en) *	2020-04-29	2021-11-04	Jun Young Choi	Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
WO2022207655A1 (en) *	2021-03-30	2022-10-06	Schott Schweiz Ag	System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
CN114177273B (zh) *	2021-11-29	2024-05-28	苏州人本药业有限公司	一种含有神经毒素的液体制剂及其制备方法
JP2025501169A (ja) *	2021-12-27	2025-01-17	エナラーレセラピューティクスインコーポレイテッド	呼吸刺激薬非経口製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57175125A (en) *	1981-04-20	1982-10-28	Wakunaga Yakuhin Kk	Preparation of beta-interferon
DE3262575D1 (en) *	1981-12-23	1985-04-18	Schering Corp	Stabilised interferon formulations and their preparation
JPS60243028A (ja) *	1984-04-28	1985-12-03	Kyowa Hakko Kogyo Co Ltd	インタ−フエロンの可溶化方法
JPS63196268A (ja) *	1987-02-10	1988-08-15	Kanegafuchi Chem Ind Co Ltd	無血清培地で継代増殖可能な形質転換細胞、その育種方法およびその細胞による蛋白質の生産方法
EP0284249A1 (en) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Lyophilized lymphokine composition
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
US4895716A (en) *	1987-06-09	1990-01-23	Biogen, Inc.	Stabilized formulations of gamma interferons
JPH02124832A (ja) *	1988-07-08	1990-05-14	Toray Ind Inc	インターヘェロンβ組成物
DE3939346A1 (de) *	1989-11-29	1991-06-06	Behringwerke Ag	Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
IL109350A (en) *	1993-05-12	2001-01-28	Genentech Inc	Stable liquid compositions of gamma interferon
TW249202B (et) *	1993-08-13	1995-06-11	Ciba Gerigy Corp
US5545723A (en) *	1994-03-15	1996-08-13	Biogen Inc.	Muteins of IFN-β
JPH09511745A (ja) *	1994-04-08	1997-11-25	ブリガムアンドウィミンズホスピタル	経口寛容および／またはタイプｉインターフェロンを用いた自己免疫疾患の治療
IT1272252B (it) *	1994-05-16	1997-06-16	Applied Research Systems	Formulazioni liquide di interferone beta
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
SI0948358T2 (sl) *	1996-12-24	2012-03-30	Biogen Idec Inc	Stabilne tekoče formulacije interferona

1997
- 1997-12-23 SI SI9730670T patent/SI0948358T2/sl unknown
- 1997-12-23 ES ES97952621T patent/ES2224290T5/es not_active Expired - Lifetime
- 1997-12-23 CN CNB971814996A patent/CN1222315C/zh not_active Expired - Lifetime
- 1997-12-23 DE DE69729880T patent/DE69729880T3/de not_active Expired - Lifetime
- 1997-12-23 WO PCT/US1997/023817 patent/WO1998028007A1/en not_active Ceased
- 1997-12-23 CN CN2005100915177A patent/CN1733296B/zh not_active Expired - Lifetime
- 1997-12-23 AT AT97952621T patent/ATE270899T1/de active
- 1997-12-23 SK SK858-99A patent/SK284989B6/sk not_active IP Right Cessation
- 1997-12-23 EE EEP200300127A patent/EE04266B1/et unknown
- 1997-12-23 NZ NZ336548A patent/NZ336548A/en not_active IP Right Cessation
- 1997-12-23 JP JP52905698A patent/JP4878664B2/ja not_active Expired - Fee Related
- 1997-12-23 EA EA199900597A patent/EA002754B1/ru not_active IP Right Cessation
- 1997-12-23 TR TR1999/01968T patent/TR199901968T2/xx unknown
- 1997-12-23 CA CA2275890A patent/CA2275890C/en not_active Expired - Lifetime
- 1997-12-23 EP EP97952621A patent/EP0948358B2/en not_active Expired - Lifetime
- 1997-12-23 DK DK97952621.7T patent/DK0948358T4/da active
- 1997-12-23 EE EEP199900313A patent/EE04223B1/et unknown
- 1997-12-23 AU AU56191/98A patent/AU738362B2/en not_active Expired
- 1997-12-23 KR KR1020077010020A patent/KR101042660B1/ko not_active Expired - Lifetime
- 1997-12-23 BR BR9714434-7A patent/BR9714434A/pt active Search and Examination
- 1997-12-23 HU HU0000829A patent/HU224222B1/hu active IP Right Grant
- 1997-12-23 PL PL97334365A patent/PL193447B1/pl unknown
- 1997-12-23 PT PT97952621T patent/PT948358E/pt unknown
- 1997-12-23 CZ CZ0228299A patent/CZ300636B6/cs not_active IP Right Cessation
- 1997-12-23 IL IL13052497A patent/IL130524A/xx not_active IP Right Cessation
- 1997-12-23 KR KR1019997005701A patent/KR20000069664A/ko not_active Ceased
1999
- 1999-06-21 IS IS5087A patent/IS2070B/xx unknown
- 1999-06-23 MX MX2012000515A patent/MX337876B/es unknown
- 1999-06-23 NO NO993121A patent/NO327844B1/no not_active IP Right Cessation
- 1999-07-19 BG BG109523A patent/BG65418B1/bg unknown
- 1999-07-19 BG BG103594A patent/BG65171B1/bg unknown
2001
- 2001-07-05 NZ NZ512792A patent/NZ512792A/xx not_active IP Right Cessation
2007
- 2007-05-18 JP JP2007133540A patent/JP2007204501A/ja not_active Withdrawn
2011
- 2011-01-07 JP JP2011002557A patent/JP5851695B2/ja not_active Expired - Lifetime
- 2011-10-04 JP JP2011220534A patent/JP2012006979A/ja not_active Withdrawn
2014
- 2014-02-25 JP JP2014033581A patent/JP2014098029A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DK0948358T4 (da)	2012-03-19
JP2007204501A (ja)	2007-08-16
AU738362B2 (en)	2001-09-13
BG65418B1 (bg)	2008-07-31
CN1245434A (zh)	2000-02-23
MX337876B (es)	2016-03-22
HUP0000829A2 (en)	2000-07-28
BG109523A (en)	2007-05-31
KR20070052363A (ko)	2007-05-21
EP0948358B1 (en)	2004-07-14
BR9714434A (pt)	2000-05-02
EA199900597A1 (ru)	2000-02-28
HK1092048A1 (zh)	2007-02-02
CA2275890C (en)	2011-11-01
ES2224290T5 (es)	2012-03-12
DE69729880T3 (de)	2012-05-10
NO327844B1 (no)	2009-10-05
CN1222315C (zh)	2005-10-12
IS2070B (is)	2005-12-15
PL193447B1 (pl)	2007-02-28
HUP0000829A3 (en)	2002-01-28
ES2224290T3 (es)	2005-03-01
TR199901968T2 (xx)	1999-12-21
JP5851695B2 (ja)	2016-02-03
DE69729880D1 (de)	2004-08-19
EE04266B1 (et)	2004-04-15
CA2275890A1 (en)	1998-07-02
ATE270899T1 (de)	2004-07-15
NO993121D0 (no)	1999-06-23
SI0948358T2 (sl)	2012-03-30
BG65171B1 (bg)	2007-05-31
PL334365A1 (en)	2000-02-28
JP2011068694A (ja)	2011-04-07
NO993121L (no)	1999-08-24
PT948358E (pt)	2004-10-29
HU224222B1 (hu)	2005-06-28
AU5619198A (en)	1998-07-17
KR101042660B1 (ko)	2011-06-20
SI0948358T1 (en)	2005-04-30
NZ512792A (en)	2002-11-26
DK0948358T3 (da)	2004-11-08
IL130524A (en)	2005-08-31
HK1025040A1 (en)	2000-11-03
EA002754B1 (ru)	2002-08-29
JP2012006979A (ja)	2012-01-12
JP4878664B2 (ja)	2012-02-15
CZ300636B6 (cs)	2009-07-08
BG103594A (en)	2000-04-28
IS5087A (is)	1999-06-21
JP2001519770A (ja)	2001-10-23
CN1733296A (zh)	2006-02-15
EE9900313A (et)	2000-04-17
SK85899A3 (en)	2000-01-18
WO1998028007A1 (en)	1998-07-02
IL130524A0 (en)	2000-06-01
EE200300127A (et)	2003-06-16
EP0948358A1 (en)	1999-10-13
DE69729880T2 (de)	2005-07-07
NZ336548A (en)	2001-09-28
SK284989B6 (sk)	2006-04-06
CN1733296B (zh)	2010-05-26
EP0948358B2 (en)	2011-11-23
CZ228299A3 (cs)	1999-12-15
JP2014098029A (ja)	2014-05-29
KR20000069664A (ko)	2000-11-25

Legal Events

Date	Code	Title	Description
2005-02-15	KB4A	Valid patent at the end of a year	Effective date: 20041231
2005-10-17	HC1A	Change of owner name
2006-02-15	KB4A	Valid patent at the end of a year	Effective date: 20051231
2007-02-15	KB4A	Valid patent at the end of a year	Effective date: 20061231
2008-02-15	KB4A	Valid patent at the end of a year	Effective date: 20071231
2009-02-16	KB4A	Valid patent at the end of a year	Effective date: 20081231
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231

Publication	Publication Date	Title
EE04266B1 (et)	2004-04-15	Interferooni stabiilne vedelkompositsioon
CA2113995A1 (en)	1993-03-18	Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
AU586892B2 (en)	1989-07-27	Pharmaceutical and dietary composition
CA2085750A1 (en)	1991-12-19	Osteoinductive pharmaceutical formulations
ES8203385A1 (es)	1982-04-01	Procedimiento de obtencion de nuevos derivados de la vin- blastina
EP2145897A3 (en)	2010-03-03	Therapeutic methods and compositions based on serrate proteins and nucleic acids
FI101938B1 (fi)	1998-09-30	Polypeptidijohdannaisia
ATE56729T1 (de)	1990-10-15	Protein mit zellwachstumsstimulierender wirkung, dessen zusammensetzung und verfahren zu seiner herstellung.
TW364850B (en)	1999-07-21	Nematocidal compositions
DE68920931D1 (de)	1995-03-16	Rekombinanter natürlicher Killerzellen-Aktivator.
AU678421B2 (en)	1997-05-29	Highly concentrated TCF pharmaceutical preparations
AU3494093A (en)	1994-08-15	S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
CA2153071A1 (en)	1994-07-21	Derivatized calcitonins
FI970667L (fi)	1997-02-17	Koostumukset
KR860003012A (ko)	1986-05-19	(-)시스-1,2-에폭시프로필포스폰산과 아미노산과의 염을 함유하는 수용성 제약 조성물